Zeria is promoting efficient and steady new drug development in Japan and overseas that includes actively allocating management resources to R&D and undertaking global clinical trials.

Zeria has built a pipeline focused on the gastrointestinal field and launched numerous pharmaceutical products throughout the world, including Acofide, an original first-in-class therapeutic agent discovered and developed by Zeria for functional dyspepsia.

Additionally, we are actively in-licensing and developing drugs that have sales track records in overseas markets with the aim of contributing to medical care.

Swiss-based Tillotts Pharma, a Zeria Group company and the originator of the ulcerative colitis therapeutic agent Asacol, is carrying out business centering on lower gastrointestinal tract treatments. Tillotts Pharma also proactively undertakes clinical development to raise the added value of products, which includes developing improved-version mesalazine formulations utilizing new formulation technologies and adding new dosage forms.

In 2018 Zeria and Tillotts Pharma built a new organization that unifies the management of R&D at both companies, with the aim of achieving efficient global development.

The management under this new organization will control the Zeria Group’s global development, thereby enabling the Group to strengthen its new drug pipeline. The Zeria Group aims to raise its global R&D capabilities to steadily provide treatments as quickly to possible to patients fighting illnesses.

Consumer Healthcare product development aims at developing products that match customer needs in a broad range of categories. These include OTC drugs that contribute to self-medication as well as quasi-drugs, cosmetics, health foods and medical devices that support extended healthy lifespans.

UP DATE 1-Aug-2024

*: Supported by a grant from Japan Agency for Medical Research and Development (AMED)